scholarly journals Advanced G‐CSF ‐producing non‐small cell lung cancer‐not otherwise specified, with favourable response to pembrolizumab monotherapy

2020 ◽  
Vol 8 (7) ◽  
Author(s):  
Yohei Matsui ◽  
Tadaaki Yamada ◽  
Naoko Masuzawa ◽  
Shinshichi Hamada ◽  
Koichi Takayama ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Favourable Response ◽  
Not Otherwise Specified

scholarly journals Impact of Non–Small-Cell Lung Cancer-Not Otherwise Specified Immunophenotyping on Treatment Outcome

2014 ◽  
Vol 9 (10) ◽  
pp. 1540-1546 ◽  
Author(s):  
Luisella Righi ◽  
Tiziana Vavalà ◽  
Ida Rapa ◽  
Simona Vatrano ◽  
Jessica Giorcelli ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Treatment Outcome ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Not Otherwise Specified

41: Audit of 'non-small cell lung cancer not – otherwise specified' diagnoses within the Northern Lung Cancer Network

Lung Cancer ◽  
2015 ◽  
Vol 87 ◽  
pp. S16
Author(s):  
C.T. McBrearty ◽  
S. Williamson ◽  
J.W. Killen
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Not Otherwise Specified ◽  
Cancer Network

Elevation in serum uric acid levels predicts favourable response to erlotinib treatment in patients with metastatic non‐small‐cell lung cancer

2019 ◽  
Vol 45 (2) ◽  
pp. 303-308
Author(s):  
Fatih Selcukbiricik ◽  
Elif Ozdogan ◽  
Tuncay Dagel ◽  
Serhan Tanju ◽  
Suat Erus ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Uric Acid ◽  
Small Cell Lung Cancer ◽  
Serum Uric Acid ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Favourable Response

scholarly journals Expression of PD-L1 Is Associated with Inflammatory Microenvironment in Surgical Specimens of Non-Small Cell Lung Cancer

2021 ◽  
Vol 11 (8) ◽  
pp. 767
Author(s):  
Ivan Simundza ◽  
Dragan Krnic ◽  
Josko Juricic ◽  
Benjamin Benzon ◽  
Rina Simundza ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Cells ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Inflammatory Microenvironment ◽  
Not Otherwise Specified ◽  
Average Survival ◽  
The Mean

The aim of this study was to analyse the expression of PD-L1 in non-small cell lung cancer (NSCLC) and its correlation with immune microenvironment response (IMR), clinic-pathological parameters, and outcome. The sample included 76 male and 32 female patients who underwent surgical resection. The mean age of the males was 66 years, and that of the females was 64 years. Adenocarcinoma (ADC) was diagnosed in 68 (63%) cases, squamous cell carcinoma in 35 (32%) cases, and NSCLC (not otherwise specified) in 5 (5%) cases. Metastatic lymph nodes were found in 38 (36%) patients, 18 with N1 nodes and 20 with N2 nodes. PD-L1 expression was valuated as the percentage of positive cancer cells among all cancer cells. Gender, age, and histologic type were not associated with PD-L1 expression (all p > 0.05). The subtypes of ADC were associated with PD-L1 expression (p = 0.050). The papillary subtype was 4.3 times more common among PD-L1 negative than PD-L1 positive ADC; the solid subtype was 1.9 times more common among PD-L1 positive than PD-L1 negative ADC. IMR was predominantly strong in 19 cases, weak in 36, and absent in 53 cases. The median value of PD-L1 expression in cancer cells was positively correlated with IMR (p = 0.039). PD-L1 expression was not correlated with overall survival (p = 0.643). The patients with strong, inflammatory-like IMR had an average survival time that was 12 months longer than patients with absent/low IMR (LR = 2.8; p = 0.132). In conclusion, the papillary subtype was more commonly PD-L1 negative in comparison with other subtypes of ADC. Positive PD-L1 expression in tumour cells was connected with strong, inflammatory-like IMR. Patients with strong IMR tended to experience better outcomes. Further investigations are needed on larger-scale cohorts to elucidate the insights of this descriptive study.

How should we manage non-small-cell lung cancer “not-otherwise-specified”?

2021 ◽  
Vol 38 (7) ◽  
Author(s):  
Young Hak Kim ◽  
Yoshihiro Nishimura ◽  
Yasuhiro Funada
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Not Otherwise Specified

Validity of using immunohistochemistry to predict treatment outcome in patients with non-small cell lung cancer not otherwise specified

2019 ◽  
Vol 145 (10) ◽  
pp. 2495-2506
Author(s):  
Takahiro Ota ◽  
Keisuke Kirita ◽  
Reiko Matsuzawa ◽  
Hibiki Udagawa ◽  
Shingo Matsumoto ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Treatment Outcome ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Not Otherwise Specified

scholarly journals P1.09-33 Validity of Non-Small Cell Lung Cancer Not Otherwise Specified to Use Immunohistochemistry on Treatment Outcome

2018 ◽  
Vol 13 (10) ◽  
pp. S562-S563
Author(s):  
T. Ota ◽  
K. Kirita ◽  
H. Udagawa ◽  
S. Umemura ◽  
S. Matsumoto ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Treatment Outcome ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Not Otherwise Specified
Sign in / Sign up

Export Citation Format

Share Document